A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study shows dabrafenib and trametinib combination therapy is safe and effective for BRAF V600E-mutated non-small cell lung cancer (NSCLC) in Japanese real-world data. Outcomes align with prior clinical trial findings.
Area Of Science
- Oncology
- Pharmacology
- Clinical Research
Background
- BRAF V600E-mutated non-small cell lung cancer (NSCLC) treatment benefits from combination therapy with dabrafenib and trametinib.
- Limited clinical trial data exists for Japanese patients with unresectable NSCLC receiving this combination therapy.
Purpose Of The Study
- To investigate the safety and effectiveness of dabrafenib and trametinib in Japanese patients with unresectable NSCLC.
- To gather real-world data on this treatment combination in a Japanese population.
Main Methods
- A post-marketing surveillance study conducted in Japan from March 2018 to August 2023.
- Analysis of safety (adverse events) and efficacy (overall response rate, progression-free survival) in patients with BRAF V600E-mutated NSCLC.
Main Results
- High incidence of adverse events (92.11%), most commonly pyrexia, NSCLC progression, and rash.
- Overall response rate (ORR) was 67.19%.
- Median progression-free survival (PFS) was 364 days, with 1-year PFS rate of 49.64%.
Conclusions
- Dabrafenib and trametinib demonstrate similar safety and efficacy in real-world Japanese patients as previously reported in clinical trials.
- This combination therapy is a viable option for BRAF V600E-mutated NSCLC in the Japanese population.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...